Cargando…

Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study

OBJECTIVE: Treatment of severe ulcerative colitis (UC) is challenging. Although the efficacy of tacrolimus (TAC) and infliximab (IFX) have been evaluated in patients with severe UC, the safety and efficacy levels of sequential therapies (TAC→IFX/IFX→TAC) in these patients remain unclear. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minami, Naoki, Yoshino, Takuya, Matsuura, Minoru, Koshikawa, Yorimitsu, Yamada, Satoshi, Toyonaga, Takahiko, Madian, Ali, Honzawa, Yusuke, Nakase, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599165/ https://www.ncbi.nlm.nih.gov/pubmed/26462273 http://dx.doi.org/10.1136/bmjgast-2014-000021

Ejemplares similares

Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis
por: Yamada, Satoshi, et al.
Publicado: (2015)

Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience
por: Yamada, Satoshi, et al.
Publicado: (2014)

Efficacy of Thiopurines in Biologic-Naive Japanese Patients With Crohn's Disease: A Single-Center Experience
por: Yoshino, Takuya, et al.
Publicado: (2015)

Diagnosis and Treatment of Ulcerative Colitis with Cytomegalovirus Infection: Importance of Controlling Mucosal Inflammation to Prevent Cytomegalovirus Reactivation
por: Nakase, Hiroshi, et al.
Publicado: (2014)

Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
por: Yokomizo, Lauren, et al.
Publicado: (2016)

Risk factors for developing colorectal cancer in Japanese patients with ulcerative colitis: a retrospective observational study—CAPITAL (Cohort and Practice for IBD total management in Kyoto-Shiga Links) study I
por: Yoshino, Takuya, et al.
Publicado: (2016)

Ulcerative colitis: Impact of early disease clearance on long‐term outcomes ‐ A multicenter cohort study
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Osteopontin Deficiency Accelerates Spontaneous Colitis in Mice with Disrupted Gut Microbiota and Macrophage Phagocytic Activity
por: Toyonaga, Takahiko, et al.
Publicado: (2015)

Long‐term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study
por: Festa, Stefano, et al.
Publicado: (2021)

High prevalence of ulcerative appendicitis in patients with ulcerative colitis
por: Heuthorst, Lianne, et al.
Publicado: (2021)

Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis
por: Hamel, Blaise, et al.
Publicado: (2018)

Usefulness of sulfasalazine for patients with refractory-ulcerative colits
por: Yoshino, Takuya, et al.
Publicado: (2016)

Fecal lactoferrin early predicts long‐term outcomes in ulcerative colitis: A post‐hoc analysis of the UNIFI and PURSUIT trials
por: Chen, Rirong, et al.
Publicado: (2023)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Menetrier’s disease exacerbating ulcerative colitis and relieved by gastrectomy
por: Kayes, Tahrima, et al.
Publicado: (2021)

Treatment-refractory ulcerative colitis responsive to indigo naturalis
por: Saiki, Julie P, et al.
Publicado: (2021)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource
por: Stournaras, Evangelos, et al.
Publicado: (2021)

Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2013)

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

Mild to moderate ulcerative colitis: Call me by my name
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2022)

Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis
por: Brookes, Matthew J, et al.
Publicado: (2020)

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)
por: Probert, Christopher SJ, et al.
Publicado: (2018)

Inflammation decreases keratin level in ulcerative colitis; inadequate restoration associates with increased risk of colitis-associated cancer
por: Corfe, Bernard M, et al.
Publicado: (2015)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis
por: Johansson, Malin E V, et al.
Publicado: (2014)

Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice
por: He, Xiaolong, et al.
Publicado: (2021)

Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis
por: van der Post, Sjoerd, et al.
Publicado: (2019)

Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study
por: Pugliese, Daniela, et al.
Publicado: (2021)

Acute appendicitis and ulcerative colitis: a population-based sibling comparison study
por: Garcia-Argibay, Miguel, et al.
Publicado: (2022)

Ulcerative colitis increases risk of hypertension in a UK biobank cohort study
por: He, Jinshen, et al.
Publicado: (2022)

Mesalazine granules promote disease clearance in patients with mild‐to‐moderate ulcerative colitis
por: Kruis, Wolfgang, et al.
Publicado: (2023)

Colectomy in patients with ulcerative colitis is not associated to future diagnosis of primary sclerosing cholangitis
por: Lundberg Båve, Aiva, et al.
Publicado: (2023)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview
por: Choi, Chang-Ho Ryan, et al.
Publicado: (2015)

Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2021)

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
por: Louis, Edouard, et al.
Publicado: (2022)

Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation
por: Allocca, Mariangela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_krrcqq6tu0kpfe1gvdu3k9empo